Sanofi Pasteur has received marketing approval from the Philippines’ Food and Drug Administration for Dengvaxia to prevent all four dengue types in individuals aged from nine to 45 years and living in endemic areas.

The approval makes dengvaxia the first vaccine to be licensed for the prevention of dengue in Asia, where approximately 67 million people contract the disease annually.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Sanofi Pasteur president and CEO Olivier Charmeil said: "Approval of the first dengue vaccine in Asia, which bears 70% of global disease burden, is a major milestone in dengue prevention and public health."

"Vaccination is widely accepted as one of the most cost-effective ways to reduce the spread of infectious diseases like dengue."

Each year, Asian endemic countries spend an estimated $6.5bn in both direct and indirect medical costs due to dengue.

Philippine Foundation for Vaccination president Dr May Book Montellano said: "Prevention of dengue is an urgent and growing medical priority in the Philippines.

See Also:

"Vaccination is widely accepted as one of the most cost-effective ways to reduce the spread of infectious diseases like dengue.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"The approval of Dengvaxia, the world’s first dengue vaccine, in the Philippines will be a critical addition to the ongoing public education and vector control efforts currently directed towards dengue prevention in our country."

Apart from the Philippines, Dengvaxia is also registered in Mexico, while regulatory review processes for the vaccine are continuing in other countries where dengue is a public health priority.

The company has already started manufacturing of the vaccine in France.

Last year, Dengvaxia completed Phase III clinical studies to evaluate the primary objective of vaccine efficacy.

The company noted that the Philippines participated in all three phases of the clinical development of Dengvaxia.